Nicolás Maduro’s regime announced Venezuela would produce Cuban Abdala coronavirus vaccine

The Venezuelan regime confirmed this Thursday that Cuban anticovid vaccine Abadala, who is on probation, It will be produced in a state laboratory in Caracas and with the formula of which he hopes to achieve mass vaccination of the population.

The Executive Vice President of Venezuela, Delcy Rodriguezhe said in a statement on public television VTV that Cuban experts visited the plant of the Socialist Society for the Production of Biological Medicines (Espromed Bio), where they checked the conditions of production of the Abdala vaccine.

Rodríguez did not say when Venezuela plans to start production of the Cuban vaccine or how many doses per month it hopes to develop..

But the Minister of Health, Carlos alvaradoHe stressed that the factory, which is run by the executive, needs to undergo some adjustments before starting vaccine manufacturing.

“Here are some measures that we must take immediately to (…) as soon as possible start manufacturing vaccines in Venezuela“, He explained.

At the end of March, the Venezuelan dictator, Nicolas maduro, said your country will participate in the third phase of testing Cuban vaccine candidates Soberana 02 and Abdala, two antidotes with which he hopes to advance mass vaccination in this South American country.

But the Venezuelan National Academy of Medicine (ANM) has warned that the Sovereign 02 and Abdala formulas “these are not vaccines“Yet, but”experimental products that are just beginning to be evaluated“.

“Venezuela is suffering from a serious epidemic of COVID-19 and, instead of participating in the testing of experimental products with unknown characteristics, it should give priority to the provision of vaccines of recognized safety and efficacy in the country “ANM said in a statement last March.

In this text, academics have expressed concern about the effectiveness of these drugs, since “the results of phases 1 and 2” of the tests are not known, and therefore it is not known “whether the products are capable of inducing in humans a level and a quality of antibodies capable of conferring protection against the virus”.

(With information from EFE)

KEEP READING: